Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Short Interest Update

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the target of a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 23,500 shares, a drop of 20.6% from the October 15th total of 29,600 shares. Based on an average daily trading volume, of 31,700 shares, the days-to-cover ratio is currently 0.7 days. Currently, 1.4% of the company’s shares are short sold.

Institutional Trading of Creative Medical Technology

An institutional investor recently bought a new position in Creative Medical Technology stock. Virtu Financial LLC acquired a new position in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 16,374 shares of the company’s stock, valued at approximately $85,000. Virtu Financial LLC owned about 1.21% of Creative Medical Technology at the end of the most recent reporting period. Institutional investors own 1.42% of the company’s stock.

Creative Medical Technology Stock Up 1.5 %

Shares of NASDAQ CELZ traded up $0.04 on Friday, reaching $2.70. 20,364 shares of the company’s stock traded hands, compared to its average volume of 71,907. The business’s 50 day simple moving average is $3.47 and its two-hundred day simple moving average is $3.70. The company has a market cap of $4.73 million, a price-to-earnings ratio of -0.71 and a beta of 2.01. Creative Medical Technology has a 12 month low of $2.52 and a 12 month high of $10.28.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.